The Tumor Necrosis Factor Ligand Superfamily Member 13B pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 13B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Ligand Superfamily Member 13B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Genito Urinary System, Hematological Disorders, and Hormonal Disorders which include the indications Systemic Lupus Erythematosus, Lupus Nephritis, IgA Nephropathy (Berger’s Disease), Antiphospholipid Syndrome, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), and Graves Diseases. It also reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13B targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Ligand Superfamily Member 13B pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 2, 1, 1, and 1 respectively.
Tumor Necrosis Factor Ligand Superfamily Member 13B overview
Tumor Necrosis Factor Ligand Superfamily Member 13B is a protein that in humans is encoded by a gene TNFSF13B. It is a cytokine and belongs to the tumor necrosis factor (TNF) ligand family. This is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. TNFSF13B is expressed in B cell lineage cells and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells.
For a complete picture of Tumor Necrosis Factor Ligand Superfamily Member 13B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
